Summarized by Masters of Longevity from Longevity Technology.
A news article about a biotech trial expansion that tripled enrollment to strengthen safety and biomarker readouts for an early-stage ALS antibody study.
Key Takeaways
- VectorY expanded its Phase 1/2 PIONEER-ALS study from 12 to 36 participants before any efficacy data were available.
- The open-label, global dose-escalation trial will assess safety, tolerability, pharmacokinetics, NfL and new TDP-43 pathway biomarkers.
- VectorY's pipeline includes additional antibodies targeting mutant HTT, TDP-43 in frontotemporal dementia, and phosphorylated tau in Alzheimer's disease.
